These forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed Forums.
Dr. Guttman / Primary Results from a Phase 2b, Randomized, Placebo-Controlled Trial of Upadacitinib for Patients with Atopic Dermatitis
Dr. Bissonnette / Efficacy and Safety of Oral ASN002, a Novel JAK/SYK inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Study.
Dr. Silverberg / Patient-reported Outcomes (PROs) from a Phase 2 Double-blinded, Randomized, Multi-center, Placebo-controlled Study of Baricitinib in Adult Patients with Moderate-to-severe Atopic Dermatitis (AD)
Dr. Thaci / MOR106, an Anti-IL-17C mAb, a Potential New Approach for Treatment of Moderate-to-severe Atopic Dermatitis: Phase 1 Study.
Ogg / Proof-of-concept Phase 2a Clinical Trial of ANB020 (anti-IL-33) in the Treatment of Moderate-to-severe Atopic Dermatitis
Dr. Gordon / Efficacy and Safety of Risankizumab: Results from Two Double-blind, Placebo- and Ustekinumab-controlled, Phase 3 Trials in Moderate-to-severe Plaque Psoriasis
Dr. Reich / Long-term Efficacy of Guselkumab Treatment After Drug Withdrawal and Retreatment in Patients with Moderate-severe Plaque Psoriasis: Results from VOYAGE 2
Dr. Papp / Dual Neutralization of Interleukin (IL)-17A and IL-17F with Bimekizumab in Moderate-to-severe Psoriasis: Results from a Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study
Dr. Gelfand / A Phase Iv, Randomized, Double-blind, Placebo-controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (The Vip-U Trial)
Yazici / Apremilast for Behçet’s Syndrome: A Phase III Randomized, Placebo-controlled, Double-blind Study
Giamarellos-Bourboulis / Efficacy of IFX-1, an Anti-C5a Monoclonal Antibody, in an Open Label Phase 2a Study in Patients with Hidradenitis Suppurativa not Eligible for Adalimumab
Dr. Baum / A Pilot Phase 2a Study of the Safety and Efficacy of Bertilimumab, an Anti-eotaxin-1 Antibody, in Bullous Pemphigoid